Wilson David Ian 4

What Happened
David Ian Wilson, a director of Neuphoria Therapeutics, received a grant of 8,537 restricted stock units (RSUs) on January 20, 2026. The RSUs were awarded with an acquisition price of $0.00 (i.e., no cash paid at grant). This transaction is an award/grant (Form 4 code A), not a purchase or sale of outstanding shares.

Key Details

• Transaction date: 2026-01-20 (reported on Form 4 filed 2026-01-21). Filing appears timely.
• Instrument: 8,537 RSUs (each RSU represents a contingent right to one share of common stock). Reported price: $0.00 at grant.
• Shares owned after transaction: not disclosed in the excerpt of this filing.
• Footnotes:
  • F1: Each RSU converts to one share upon settlement.
  • F2: Grant made pursuant to the Company’s Board annual remuneration policy.
  • F3: RSUs vest only if the reporting person remains in continuous service through either (a) the day before the Company’s next annual meeting (expected by Dec 15, 2026) or (b) the effective date of a change in control.
• Transaction type: Award/Grant (A); derivative award subject to vesting, not an immediate share transfer.

Context
RSU grants are compensation and do not reflect an open-market purchase or sale; they provide a contingent right to future shares once vesting conditions are met. Because these RSUs vest based on continued service (or a change in control), they represent deferred equity compensation rather than an immediate change in ownership or liquidity.